Patterns of use of Schedule II stimulants in 2020
| Adult use, no (%) | |
| All users | 276 223 (100.0) |
| Continuous | 157 081 (56.9) |
| New starts | 79 407 (28.8) |
| Stopped | 67 469 (24.4) |
| Exposure, median (IQR) | |
| Treatment days | 227 (110–322) |
| Stimulant prescriptions | 8 (4–11) |
| Total CNS-active prescriptions | 15 (9–26) |
Source: MarketScan Research Databases, 2019–2020, commercially insured adults, age 19–64 years. Schedule II stimulants include amphetamine and methylphenidate drug products.
CNS, central nervous system.